Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9H410
UPID:
DSN1_HUMAN
Alternative names:
-
Alternative UPACC:
Q9H410; B4DWT2; E1P5U9; Q5JW55; Q5JW56; Q9H8P4
Background:
Kinetochore-associated protein DSN1 homolog plays a pivotal role in mitosis, being a crucial component of the MIS12 complex. This complex is essential for proper chromosome alignment, segregation, and kinetochore formation, processes fundamental for cell division.
Therapeutic significance:
Understanding the role of Kinetochore-associated protein DSN1 homolog could open doors to potential therapeutic strategies. Its critical function in cell division highlights its potential as a target in cancer therapy, where cell division is often unregulated.